CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 Study of Replication Competent Reovirus (Reolysin®) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02444546
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:12.263545+00:00
Published At: 2023-04-24T00:00:00+00:00
Record Updated At: 2023-04-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Childhood Astrocytoma", "Childhood Atypical Teratoid/Rhabdoid Tumor", "Diffuse Intrinsic Pontine Glioma", "Glioma", "Recurrent Childhood Anaplastic Oligodendroglioma", "Recurrent Childhood Brain Neoplasm", "Recurrent Childhood Glioblastoma", "Recurrent Childhood Medulloblastoma", "Recurrent Primitive Neuroectodermal Tumor", "Refractory Brain Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-04-24"
protocolSection.identificationModule.nctId: "NCT02444546"
protocolSection.identificationModule.officialTitle: "Phase 1 Study of Replication Competent Reovirus (Reolysin\u00ae) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain Tumors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.